These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 12930038)

  • 1. Sickle cell crisis and endothelin antagonists.
    Angerio AD; Lee ND
    Crit Care Nurs Q; 2003; 26(3):225-9. PubMed ID: 12930038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and perspective of endothelin-1 antagonism in acute heart failure.
    Kiowski W; Suetsch G; Oechslin E; Schalcher C; Brunner-Larocca HP; Bertel O
    J Cardiovasc Pharmacol; 2001 Nov; 38 Suppl 2():S53-7. PubMed ID: 11811379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelin receptor antagonism prevents hypoxia-induced mortality and morbidity in a mouse model of sickle-cell disease.
    Sabaa N; de Franceschi L; Bonnin P; Castier Y; Malpeli G; Debbabi H; Galaup A; Maier-Redelsperger M; Vandermeersch S; Scarpa A; Janin A; Levy B; Girot R; Beuzard Y; Leboeuf C; Henri A; Germain S; Dussaule JC; Tharaux PL
    J Clin Invest; 2008 May; 118(5):1924-33. PubMed ID: 18382768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bosentan attenuates sickle cell disease erythrocyte HbS polymerization and impaired deformability induced by endothelin-1.
    Rosa Teixeira-Alves L; Guimarães-Nobre CC; Mendonça-Reis E; Miranda-Alves L; Berto-Junior C
    Can J Physiol Pharmacol; 2023 Dec; 101(12):642-651. PubMed ID: 36821840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endothelin and endothelin antagonists in hypertension.
    Schiffrin EL
    J Hypertens; 1998 Dec; 16(12 Pt 2):1891-5. PubMed ID: 9886874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of pain in pediatric sickle cell disease: understanding the balance between endothelin mediated vasoconstriction and apelin mediated vasodilation.
    Smith TP; Schlenz AM; Schatz JC; Maitra R; Sweitzer SM
    Blood Cells Mol Dis; 2015 Feb; 54(2):155-9. PubMed ID: 25486928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma endothelin-1, cytokine, and prostaglandin E2 levels in sickle cell disease and acute vaso-occlusive sickle crisis.
    Graido-Gonzalez E; Doherty JC; Bergreen EW; Organ G; Telfer M; McMillen MA
    Blood; 1998 Oct; 92(7):2551-5. PubMed ID: 9746797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective and non-selective ET antagonists reveal an ET(A)/ET(B) receptor mediated ET-1-induced antinociceptive effect in PAG area of mice.
    D'Amico M; Di Filippo C; Rossi F
    Life Sci; 1997; 61(25):PL 397-401. PubMed ID: 9416772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling.
    Mulder P; Richard V; Derumeaux G; Hogie M; Henry JP; Lallemand F; Compagnon P; Macé B; Comoy E; Letac B; Thuillez C
    Circulation; 1997 Sep; 96(6):1976-82. PubMed ID: 9323089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelin B receptor-mediated vasoconstriction induced by endothelin A receptor antagonist.
    Zhang Y; Oliver JR; Horowitz JD
    Cardiovasc Res; 1998 Sep; 39(3):665-73. PubMed ID: 9861310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bosentan the mixed endothelin-A- and -B-receptor antagonist suppresses intrapericardial endothelin-1-induced ventricular arrhythmias.
    Horkay F; Gellér L; Kiss O; Szabó T; Vagó H; Kékesi V; Juhász-Nagy A; Merkely B
    J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S320-2. PubMed ID: 11078409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endothelin receptor antagonists in sickle cell disease: A promising new therapeutic approach.
    Fox BM; Kasztan M
    Life Sci; 2016 Aug; 159():15-19. PubMed ID: 27049871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelin type A receptors mediate pain in a mouse model of sickle cell disease.
    Lutz BM; Wu S; Gu X; Atianjoh FE; Li Z; Fox BM; Pollock DM; Tao YX
    Haematologica; 2018 Jul; 103(7):1124-1135. PubMed ID: 29545351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of bosentan, pinacidil and nitroprusside on human pulmonary arteries: comparison with rat pulmonary arteries.
    Wanstall JC; Kay CS; O'Donnell SR; Wilson K; Cole PH; Matar K
    Fundam Clin Pharmacol; 1997; 11(6):584-91. PubMed ID: 9444527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelin-1 induced bronchial hyperresponsiveness in the rabbit: an ET(A) receptor-mediated phenomenon.
    D'Agostino B; Gallelli L; Falciani M; Di Pierro P; Rossi F; Filippelli A; Rossi F
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Dec; 360(6):665-9. PubMed ID: 10619183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events.
    Heeney MM; Hoppe CC; Abboud MR; Inusa B; Kanter J; Ogutu B; Brown PB; Heath LE; Jakubowski JA; Zhou C; Zamoryakhin D; Agbenyega T; Colombatti R; Hassab HM; Nduba VN; Oyieko JN; Robitaille N; Segbefia CI; Rees DC;
    N Engl J Med; 2016 Feb; 374(7):625-35. PubMed ID: 26644172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vasoactive factors in sickle cell disease: in vitro evidence for endothelin-1-mediated vasoconstriction.
    Ergul S; Brunson CY; Hutchinson J; Tawfik A; Kutlar A; Webb RC; Ergul A
    Am J Hematol; 2004 Jul; 76(3):245-51. PubMed ID: 15224360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endothelin-1 is involved in stretch-induced early activation of B-type natriuretic peptide gene expression in atrial but not in ventricular myocytes: acute effects of mixed ET(A)/ET(B) and AT1 receptor antagonists in vivo and in vitro.
    Magga J; Vuolteenaho O; Marttila M; Ruskoaho H
    Circulation; 1997 Nov; 96(9):3053-62. PubMed ID: 9386175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addressing challenges of clinical trials in acute pain: The Pain Management of Vaso-occlusive Crisis in Children and Young Adults with Sickle Cell Disease Study.
    Nottage KA; Hankins JS; Faughnan LG; James DM; Richardson J; Christensen R; Kang G; Smeltzer M; Cancio MI; Wang WC; Anghelescu DL
    Clin Trials; 2016 Aug; 13(4):409-16. PubMed ID: 27000103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endothelin receptor blockade reduces ventricular dysfunction and injury after reoxygenation.
    Pearl JM; Nelson DP; Wagner CJ; Lombardi JP; Duffy JY
    Ann Thorac Surg; 2001 Aug; 72(2):565-70. PubMed ID: 11515898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.